P53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma.

ABSTRACT: Survival for patients diagnosed with mantle cell lymphoma (MCL) has improved drastically in recent years. However, patients carrying mutations in tumour protein p53 (TP53) do not benefit from modern chemotherapy-based treatments and have poor prognosis. Thus, there is a clinical need to identify missense mutations through routine analysis to enable patient stratification. Sequencing is not widely implemented in clinical practice for MCL, and immunohistochemistry (IHC) is a feasible alternative to identify high-risk patients. The aim of the present study was to investigate the accuracy of p53 as a tool to identify patients with TP53 missense mutations and the prognostic impact of overexpression and mutations in a Swedish population-based cohort. In total, 317 cases were investigated using I

SUBMITTER: Rodrigues JM 

PROVIDER: S-EPMC7754513 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature